Neglected tropical diseases, such as African trypanosomiasis, affect millions of the poorest people in the world and trigger devastating socioeconomic impacts in rural areas of sub-Saharan Africa. African trypanosomiasis, also known as sleeping sickness, is a lethal disease caused by the flagellated eukaryotic parasite Typanosoma brucei. No vaccines are available due to the ability of the parasite to evade the host immune response. The imperative need of new treatments lays the foundations for my studies, which are focused on the identification and characterization of potential drug targets of T. brucei and the identification of lead compounds to pursue in drug development efforts. Because these parasites completely rely on their cytoskeleton to complete essential processes, they are vulnerable to attack by drugs that target cytoskeletal proteins. Using a combination of molecular biology, cell biology, genetic, biochemical, and imaging techniques, I am working to identify a new class of anti-trypanosomal agents that target kinesins, a superfamily of molecular motor proteins that move cargo along microtubules.